Intelligent Investor

Acrux Limited (ASX: ACR) - Announcements

Current share price for ACR : $0.062 0.003 (4.62%)

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$18 Appendix 3Y Geoff Brooke 28 Oct 2022 9:19AM $0.082 $0.062 $0.060 fallen by 24.39%
$18 Appendix 3Y Ross Dobinson 28 Oct 2022 9:18AM $0.082 $0.062 $0.060 fallen by 24.39%
$18 Application for quotation of securities - ACR 28 Oct 2022 9:18AM $0.082 $0.062 $0.060 fallen by 24.39%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2022 9:06AM $0.082 $0.062 $0.060 fallen by 24.39%
$18 R&D Tax Incentive receipt - Overseas Finding 27 Oct 2022 9:57AM $0.082 $0.062 $0.060 fallen by 24.39%
$18 Notice of Annual General Meeting/Proxy Form 21 Oct 2022 8:21AM $0.073 $0.062 $0.060 fallen by 15.07%
$18 Application for quotation of securities - ACR 17 Oct 2022 9:05AM $0.066 $0.062 $0.060 fallen by 6.06%
$18 Remaining balance of R&D Tax Incentive Rebate received 3 Oct 2022 9:32AM $0.057 $0.062 $0.060 risen by 8.77%
$18 R&D Tax Incentive Rebate received 26 Sep 2022 9:48AM $0.063 $0.062 $0.060 fallen by 1.59%
$18 Notification of cessation of securities - ACR 30 Aug 2022 8:20AM $0.060 $0.062 $0.060 risen by 3.33%
$18 Appendix 3Y - Brumley 30 Aug 2022 8:20AM $0.060 $0.062 $0.060 risen by 3.33%
$18 Application for quotation of securities - ACR 30 Aug 2022 8:18AM $0.060 $0.062 $0.060 risen by 3.33%
$18 Appendix 4G and Corporate Governance Statement 26 Aug 2022 9:14AM $0.060 $0.062 $0.060 risen by 3.33%
$18 Appendix 4E and FY22 Annual Report 26 Aug 2022 9:12AM $0.060 $0.062 $0.060 risen by 3.33%
$18 Acrux's sixth generic dossier accepted by FDA for review 8 Aug 2022 9:33AM $0.055 $0.062 $0.060 risen by 12.73%
$18 Updated Corporate Policy - Code of Conduct 28 Jun 2022 12:14PM $0.056 $0.062 $0.060 risen by 10.71%
$18 Appendix 3Y - Oldham 22 Jun 2022 1:43PM $0.065 $0.062 $0.060 fallen by 4.62%
$18 Application for quotation of securities - ACR 22 Jun 2022 1:36PM $0.065 $0.062 $0.060 fallen by 4.62%
$18 Acrux announces commercial agreement with Padagis 20 Jun 2022 9:51AM $0.064 $0.062 $0.060 fallen by 3.13%
$18 Successful patent litigation outcome 30 May 2022 9:16AM $0.066 $0.062 $0.060 fallen by 6.06%
$18 Appendix 3Y - Brumley 23 May 2022 10:02AM $0.070 $0.062 $0.060 fallen by 11.43%
$18 Appendix 3Y - Dobinson 23 May 2022 10:01AM $0.070 $0.062 $0.060 fallen by 11.43%
$18 Application for quotation of securities - ACR 23 May 2022 9:56AM $0.070 $0.062 $0.060 fallen by 11.43%
$18 Notification of cessation of securities - ACR 14 Apr 2022 9:42AM $0.090 $0.062 $0.060 fallen by 31.11%
$18 Application for quotation of securities - ACR 14 Apr 2022 9:36AM $0.090 $0.062 $0.060 fallen by 31.11%

76 - 100 of 548 results

Page 4 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.